drugset / Trial / NCT03919383
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with toripalimab in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2019-04-15
- Primary completion
- 2019-12-01
- Completion
- 2019-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “No participants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |